E.g., 25/10/2021
E.g., 25/10/2021

bioMérieux announces the CE marking of TB IGRA® test on VIDAS®  

Today marks World Tuberculosis (TB) Day and bioMérieux, a world leader in the field of in vitro diagnostics, announces the CE marking of its innovative and fully-automated test VIDAS® TB IGRA (Interferon-Gamma Release Assay) to diagnose latent TB infection.

24 March, 2021

Tuberculosis continues to be a major global health problem. With 10 million new active cases and 1.4 million related deaths worldwide in 20191, TB remains an important cause of mortality from a single infectious disease. 

It is estimated that a fourth of the global...

BIOFIRE® Respiratory 2.1 (RP2.1) Panel with SARS-CoV-2 obtains De Novo FDA Authorization

Marcy l’Étoile (France) – bioMérieux, a world leader in the field of in vitro diagnostics, today announced that BioFire Diagnostics, its subsidiary specialized in molecular syndromic infectious disease testing, has received U.S. Food and Drug Administration (FDA) De Novo authorization for the BIOFIRE® RP2.1 Panel. 

18 March, 2021

This panel allows for the detection of 22 viral and bacterial pathogens responsible for respiratory infections, including SARS-CoV-2 (the cause of COVID-19 disease). The panel is the first SARS-CoV-2 diagnostic test of any kind that has been granted De Novo status by U.S. FDA, having gone...

The Biotech Digital Campus joins forces with biotechnology schools and training organizations to develop the talents of tomorrow

09 March, 2021

An unprecedented alliance serving the French bioproduction sector

"Recipient of a Future...

bioMérieux – 2020 Financial Results

24 February, 2021

  • €3,118 million in full-year 2020 sales, up 19.7 % like-for-like
  • Robust sales performance in the fourth quarter, with organic growth of 20.5 % led by sales of molecular biology reagents
  • Contributive operating...

bioMérieux announces the CE marking of NEPHROCHECK® test on VIDAS®

Marcy l’Etoile, France – February 3rd , 2021 – bioMérieux, a world leader in the field of in vitro diagnostics, today announced the CE marking of the innovative NEPHROCHECK® assay to detect kidney stress in patients at risk of acute kidney injury (AKI).

03 February, 2021

AKI is a common complication, affecting between 7 and 18% of all hospitalized patients1 and up to 50% of critically ill patients2. The condition is associated with a 10-fold increase in hospital mortality and a higher rate of chronic kidney disease among post-op patients...

bioMérieux announces the CE marking of its molecular biology ARGENE® test for the simultaneous detection of SARS-CoV-2, influenza viruses A and B, and RSV and hMPV viruses

Marcy l’Etoile, France – December 16, 2020 – bioMérieux, a world leader in the field of in vitro diagnostics, has announced the expansion of its ARGENE® range for the real-time PCR (RT-PCR) detection of SARS-CoV-2: the SARS-COV-2 RESPI R-GENE® test has received CE marking and is now commercially available.  

16 December, 2020

 
This high-throughput test,...

The French bioproduction sector announces the creation of Campus Biotech Digital, a platform unique in the world for bioproduction training

An ambitious goal to develop the skills necessary for health independence

14 December, 2020

As part of its contract*, the French bioproduction sector is launching an ambitious training platform: Campus Biotech Digital. Unique in the world in the bioproduction field, it will help develop skills in this field to meet new technological challenges. Covering the entire bioproduction chain,...

Increased outlook for full-year 2020

Marcy l'Étoile, December 14,  2020 – bioMérieux, a world leader in the field of in vitro diagnostics, today released its adjusted outlook for full-year 2020.  

14 December, 2020

  • Full-year 2020 net sales are now expected to be around 18% at constant exchange rates and scope of consolidation and contributive operating income before non-recurring items  about €600 million. 
  • As a reminder, this...

BIOASTER, Université de Technologie de Compiègne, Hospices Civils de Lyon and bioMérieux formalize strategic collaboration to conduct Next Generation Sequencing technology evaluation in microbiology  

Lyon, December 2, 2020 - BIOASTER Microbiology Technology Research Institute announced a strategic partnership in the field of sequencing-based diagnostics in microbiology with the Université de Technologie de Compiègne (UTC), bioMérieux, a world leader of in vitro diagnostics and the Hospices Civils de Lyon.  

02 December, 2020

In the last decade, Next Generation Sequencing technologies have transformed the field of diagnostics in microbiology. BIOASTER is proud to partner with renowned academic and industrial actors to speed up transformation of this promising technology towards diagnostic tools useful for...

bioMérieux announces the expansion of the CE marking of its molecular biology ARGENE® SARS-CoV-2 diagnostic test to include saliva specimens.  

Marcy l’Etoile, France – November 16, 2020 – bioMérieux, a world leader in the field of in vitro diagnostics, has announced the expansion of its ARGENE® range for the detection of SARS-CoV-2. As a complement to nasopharyngeal swab specimens, the singleplex SARS-CoV-2 R-GENE® real-time PCR test may now be used on saliva and oropharyngeal (throat) swab specimens for the detection of the virus that causes COVID-19. This development helps optimize laboratory workflows.

16 November, 2020

The CE-marked SARS-CoV-2 R-GENE® test covers the above three sample types. This allows bioMérieux to address the recommendation issued by the French National Authority for Health (HAS) on September 18, 2020, which encourages the preferential use of saliva swabs to test symptomatic...